YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Zillow downgraded, Global Payments upgraded: Wall Street's top analyst calls The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as co…
More than 100 patients treated with ronde-cel in 2L and 3L+ LBCL, with a manufacturing success rate of 97%No Grade ≥ 3 CRS and low rates of Grade ≥ 3 ICANS, supporting outpatient administrationTranslational data support biological basis fo…
SOUTH SAN FRANCISCO, Calif., June 04, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor (CAR) T-cell therapies for patients wit…
[Young female scientist working in laboratory] Solskin Pharmaceutical (PJP [https://seekingalpha.com/symbol/PJP]), (XPH [https://seekingalpha.com/symbol/XPH]), (PPH [https://seekingalpha.com/symbol/PPH]) and biotechnology stocks (XBI [http…
For Immediate Releases Chicago, IL – December 26, 2025 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financia…
The drug and biotech sector witnessed a see-saw performance in 2025. After a weak show for most of the year, the sector picked up in the past couple of months. This can be attributed to improved policies following several large drugmakers’…
VANCOUVER, British Columbia, Dec. 24, 2025 (GLOBE NEWSWIRE) -- Equity InsiderNews Commentary – The U.S. oncology market is projected to surge from $81 billion in 2025 to $212 billion by 2034[1], driven by a fundamental shift in how physici…
(RTTNews) - Lyell Immunopharma (LYEL) presented new clinical data from its ongoing Phase 1/2 trial of Ronde-cel in patients with relapsed or refractory large B-cell lymphoma in both the second-line and the third- or later-line settings at…
93% overall response and 76% complete response rates with median progression-free survival of 18 months in patients with large B-cell lymphoma in the 3L+ setting83% overall response and 61% complete response rates in cohort comprised predo…
[Cancer cells vis] koto_feja/E+ via Getty Images Lyell Immunopharma (LYEL [https://seekingalpha.com/symbol/LYEL]) announced its acquisition of exclusive global rights to LYL273, a CAR T-cell therapy aimed at treating metastatic colorectal…
LYL273 has demonstrated a 67% overall response rate, an 83% disease control rate, and a manageable safety profile at the highest dose level studied to date in patients with refractory metastatic colorectal cancer enrolled in an ongoing U.S…
SOUTH SAN FRANCISCO, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation CAR T-cell therapies for patients with cancer, today announced th…
Lyell Immunopharma (NASDAQ:LYEL) President and CEO Lynn Seely sold a total of 797 shares of common stock on August 11 and 12, 2025. The sales, which covered tax withholding obligations from vested restricted stock units, amounted to $8,312…
LYELL IMMUNOPHARMA INC (NASDAQ:LYEL [https://www.chartmill.com/stock/quote/LYEL]) REPORTS Q2 2025 EARNINGS: NARROWER LOSS THAN EXPECTED, CLINICAL PROGRESS IN FOCUS Lyell Immunopharma Inc released its second-quarter 2025 financial results,…
* Lyell Immunopharma press release [https://seekingalpha.com/pr/20198605-lyell-immunopharma-reports-business-highlights-and-financial-results-for-the-second-quarter] (NASDAQ:LYEL [https://seekingalpha.com/symbol/LYEL]): Q2 net loss of $42.…
Presented positive new clinical data demonstrating high rates of durable complete responses from the Phase 1/2 trial of LYL314 for the treatment of aggressive large B-cell lymphomaInitiated the PiNACLE pivotal trial of LYL314 in patients w…
* Lyell Immunopharma (NASDAQ:LYEL [https://seekingalpha.com/symbol/LYEL]) announced on Friday that it has entered into a securities purchase agreement for a private placement with certain institutional and other accredited investors, for g…
SOUTH SAN FRANCISCO, Calif., July 25, 2025 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage company advancing next-generation CAR T-cell therapies for patients with cancer, today announced that it has entered i…
* Lyell Immunopharma (NASDAQ:LYEL [https://seekingalpha.com/symbol/LYEL]) registers 625,000 common shares for resale by selling stockholders. * Shares were issued as additional merger consideration under the October 2024 merger agreement w…
SOUTH SAN FRANCISCO, Calif., June 23, 2025 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage company advancing next-generation CAR T-cell therapies for patients with cancer, announced today that members of its s…
SOUTH SAN FRANCISCO, Calif., June 23, 2025 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage company advancing next-generation CAR T-cell therapies for patients with cancer, announced today that members of its s…
LYL314 demonstrated robust clinical responses, with an 88% overall response rate and a 72% complete response rate in patients treated in the third- or later-line setting (N = 25)71% of patients with complete response remained in complete r…
* Lyell Immunopharma (NASDAQ:LYEL [https://seekingalpha.com/symbol/LYEL]) Monday announced [https://seekingalpha.com/pr/20130757-lyell-immunopharma-strengthens-clinical-and-commercial-capabilities-with-key-board-and] the appointment of Mar…
Mark J. Bachleda, PharmD, MBA appointed as independent member of the Board of DirectorsDavid Shook, MD appointed as Chief Medical Officer, Mark Meltz, JD as General Counsel and Corporate Secretary, and Jarrad Aguirre, MD, MBA as Senior Vic…
SOUTH SAN FRANCISCO, Calif., June 04, 2025 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage company advancing a pipeline of next-generation CAR T-cell therapies for patients with cancer, announced today that me…
Presenting new clinical data from Phase 1/2 multi-center clinical trial of LYL314, a next-generation dual‑targeting CD19/CD20 CAR T-cell product candidate for the treatment of relapsed and/or refractory large B‑cell lymphoma at the 18th In…
SOUTH SAN FRANCISCO, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage company advancing a pipeline of next-generation CAR T-cell therapies for patients with cancer, today announced that an…
We recently published a list of 15 Cheapest Stocks Insiders Are Buying In March. In this article, we are going to take a look at where Lyell Immunopharma, Inc. (NASDAQ:LYEL) stands against other cheapest stocks insiders are buying in March…
Acquired ImmPACT Bio and strengthened clinical pipeline with the addition of IMPT-314, a next-generation dual-targeting CD19/CD20 CAR T-cell product candidate for the treatment of aggressive large B-cell lymphoma (LBCL)Presented positive i…
SOUTH SAN FRANCISCO, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors, today anno…
Extended funding of operations into 2027 by prioritizing investment in core clinical candidates and research platform value drivers as well as de-prioritizing selected early-stage research programsRemain on track to release initial clinica…
SOUTH SAN FRANCISCO, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors, is present…
SOUTH SAN FRANCISCO, Calif., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors, announced…
Proof-of-concept manufacturing to be provided by Cellares for a key Lyell CAR T-cell therapy using Cellares' exclusive Cell Shuttle Collaboration to evaluate potential utilization of the Cell Shuttle for future Lyell CAR T-cell clinical tr…
SOUTH SAN FRANCISCO, Calif., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors, today anno…
Cash, cash equivalents and marketable securities of $632.7 million as of June 30, 2023 support advancing multiple product candidates through key clinical milestones Remain on track for initial clinical data from two lead product candidates…